Castle Biosciences says DecisionDx-Melanoma i31-SLNB beats MIA nomogram in prospective SLNB risk study

Castle Biosciences

Castle Biosciences

CSTL

0.00
  • Castle Biosciences announced publication of a prospective multicenter DECIDE study evaluating its DecisionDx-Melanoma i31-SLNB test in cutaneous melanoma.
  • Results were presented as newly published findings in Dermatology and Therapy, not as a future conference readout.
  • The study concluded i31-SLNB better separated patients who could likely skip sentinel lymph node biopsy from those who should consider it.
  • It outperformed the Melanoma Institute Australia nomogram, reducing misclassification near guideline decision thresholds used to guide biopsy use.
  • Data covered 912 patients, supporting broader clinical adoption of tumor-biology testing to refine surgical staging decisions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606251630PR_NEWS_USPR_____DA92577) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.